Zydus Cadila enters $8-bn US specialty pain market by buying Sentynl

Commenting on the development, Pankaj Patel, chairman and managing director, Zydus Cadila, said, “We have always looked at opportunities that can add value to our operations and the acquisition of Sentynl opens up a new business avenue for us in the specialty prescription segment in the US. With a strong commitment to offer effective treatment solutions with a focus on pain management, this new development offers us a platform to launch more specialty products in the US market.”

Sentynl is a San Diego-based commercial-stage specialty pharma company which specialises in launching unique products and revitalising marketed brands. With a strong focus on specialised products, Sentynl sources niche and effective products designed to treat pain and other central nervous system (CNS) conditions. 

The acquisition is solely funded by Bank of Tokyo-Mitsubishi UFJ. Leerink Partners LLC acted as exclusive financial advisor to Sentynl on the transaction.